|
Travaux scientifiques
Publications
X = niveau national et X = niveau
international
La présence de * ou de
* indique que
le papier a été vu par des examinateurs.
Correspondant à la thèse
1* Condensation d'aldéhydes
a-éthyléniques
de type R–CH–CH=CH–CHO sur l'aldéhyde
cinnamique en milieu hétérogène. Préparation
de fluorénones substituées.
J. Wiemann, J.-J. Godfroid,
C. R. Acad. Sci., 1962, 255,
2608
2* Condensations d'aldéhydes
a-éthyléniques en milieu hétérogène. I. Condensation du
méthyl-2 penténal sur les aldéhydes ortho et
paraméthylcinnamiues. II. Condensation de l'a-phénylcrotonal
sur les aldéhydes de formule R–CH=CH–CHO.
J.-J. Godfroid,
C. R. Acad. Sc., 1963, 257,
2296
3* Condensations catalytiques
d'aldéhydes
a-éthyléniques en milieu hétérogène et en phase vapeur. I.
Identification des produits de la réaction.
Synthèse d'alcoylfluorénones.
J.-J. Godfroid,
Bull. Soc. Chim., 1964, 2929
4* Condensations catalytiques
d'aldéhydes
a-éthyléniques
en milieu hétérogène et en phase vapeur. II.
Contribution à l'étude du mécanisme.
J.-J. Godfroid,
Bull. Soc. Chim., 1964,
2943.
5* Condensations catalytiques
d'aldéhydes
a-éthyléniques
en milieu hétérogène et en phase vapeur.
III. étude spectroscopique dans la série des
formylbiphényles et des alcoylfluorénones
obtenues.
J.-J. Godfroid,
Bull. Soc.
Chim.,
1964, 2953.
Travaux effectués au service des Poudres
6 Réduction de dérivés nitrés
aromatiques. Application à la synthèse
d'azobenzènes o,o'-disubstitués (rapport).
J.-J. Godfroid,
Direction des Poudres, Laboratoire de la
Commission des Substances Explosives,
note technique n°306, 1964.
Travaux post-thèse
7* Condensations mixtes d'aldéhydes
a-éthyléniques
de type R'-Ch=CR-CHO sur la benzylidène
acétone.
J. Wiemann,
N. Ronzani,
J.-J. Godfroid,
C.R. Acad. Sci., 1963, 256,
4677.
8* Condensations catalytiques d'aldéhydes
a--éthyléniques
en milieu hétérogène et en phase vapeur. IV.
Condensation entre les aldéhydes de formule
R'-CH2-CH=CR-CHO
et respectivement le crotonal, l'aldéhyde
paraméthyl cinnamique et la
a--(furyl-2) acroléine.
J.-J. Godfroid,
P. Lepoutère,
N. Ronzani, Bull. Soc. Chim., 1966, 3238.
9* Autocondensation de l'oxyde de
mésityle sur magnésie à différentes
pressions. I-. Identification des produits
de la réaction.
A. Roger,
J.-J. Godfroid, J. Wiemann,
Bull. Soc. Chim., 1967, 3030.
10*
Synthèse d'alcoyl-méthoxy-2 biphényles
d'intérêt oestrogène.
G. Lasnier,
J.-J. Godfroid,
J. Wiemann, Eur. J. Med.
Chem.,
Chimie Thérapeutique, 1967, 2;
240-245.
11* Condensations mixtes d'aldéhydes et de
cétones
a--éthyléniques
par catalyse hétérogène et en phase vapeur.
II- Condensation entre la furfurylidène
acétone et les aldéhydes de formule
R'-CH-CH=CR-CHO.
Wiemann, N. RonzaniI,
J.-J. Godfroid,
Annales de Chimie, 1967,
269.
12* Condensations mixtes
d'aldéhydes et de cétones
a--éthyléniques
par catalyse hétérogène et en phase vapeur
(1ère partie).
J. Wiemann,
N. Ronzani,
J.-J. Godfroid,
Bull. Soc.
Chim.,
1967, 2935.
13* Autocondensation de l'oxyde de mésityle sur
magnésie à différentes pressions. II- Etude
des mécanismes de réaction.
J. WiemannN,
N. Ronzani,
J.-J. Godfroid,
Bull. Soc. Chim., 1968,
2590.
14* Condensations catalytiques d'aldéhydes
a--éthyléniques
en milieu hétérogène et en phase vapeur.
V. Condensation à différentes pressions
entre l'a-a-phénylcrotonal
et les aldéhydes de formule R'-CH=CR-CHO.
Etude spectroscopique des produits obtenus.
J.-J. Godfroid,
N.
Ronzani, G. Lasnier,,
J.
Wiemann, Bull. Soc.
Chim., 1968, 4645.
15* Identification et étude
conformationnelle de cyclohexadiènes-1,3
substitués par résonance magnétique
nucléaire.
G. Lasnier,
N. Ronzani,
J.-J. Godfroid,
Bull. Soc.
Chim.,
1971, 3059.
Travaux effectués au CERPHA (Laboratoire Anphar)
16*
Quelques aspects récents de la chimie des
diurétiques (revue)
J.-J.Godfroid,
Eur. J.Med. Chem., 1968, 3,
76.
17* Chimie et pharmacologie de la Clofezone (revue).
J. Thuillier, P. Bessin,
F. Geffroy, J.-J. Godfroid,
Eur. J. Med. Chem., Chimie
Thérapeutique, 1968, 3, 53-67.
Travaux effectués sous ma responsabilité, dans
le cadre du Laboratoire de Pharmacochimie
Moléculaire et de l’Unité Pharmacochimie
Moléculaire et Systèmes Membranaires.
18 Relation structure-activité dans le
domaine des agents anti-inflammatoires
non:stérolïdiens. I. Effet en "para" dans
une série d'acides naphtylacétiques (pli
cacheté).
E. Fromant,
E. Vauthier, J.-J. Godfroid,
pli cacheté n° 107 à la
Société de Chimie Thérapeutique, 1972.
19 Corrélations structure-activité dans
le domaine des agents anti-inflammatoires
non stéroïdiens. II. Etude par la méthode de
Hansch d'une série d'acides phényl-4
naphtalène acétique (pli cacheté).
E. Fromant,
E. Vauthier, J.-J. Godfroid,
pli cacheté n° 108 à la Société de
Chimie Thérapeutique, 1973.
20* Etude stéréodynamique par RMN
d'antivitamines K de la série du Dicoumarol,
nature du processus dynamique l'influençant.
C. Laruelle,
J.-J. Godfroid,
C. Courteix,
Bull. Soc. Chim., 1974, 2111.
21
Action of biphenyl substituted molecules and
derivatives on the unicellular Algae
Dunaliella bioculata (Chlorophycea) and
Amphidinium carteri (Dinoflagellata).
Experiments to establish correlation between
the chemical structure and toxicity (résumé
publié)
E. Matthys-Rochon,
C. Blanchard-Babillot,
J.-J. Godfroid,
Compte-rendu du Colloque Européen "Problèmes
posés par la contamination de l'Homme et de
son milieu par les pesticides et les
composés organo-halogénés persistants",
1974, 22.
22 Problèmes soulevés dans l'application de
la méthode de Hansch. Quelques exemples dans
les domaines pharmacologique et
toxicologique (revue).
J.-J. Godfroid,
C. Laruelle, E. Fromant,
F.
Heymans dans "Relations
structure-activité", Société de Chimie
Thérapeutique, Ed., 1975, 93-110.
23*
Quantitative Structure-Activity
Relationships for dicoumarol antivitamines K
in the uncoupling of mitochondrial oxidative
phosphorylation.
R. Labbe-Bois,
C. Laruelle, J.-J. Godfroid,
J. Med.
Chem.,
1975, 18, 85-90.
24
An attempt at quantitative
structure-activity relationships (QSAR) in
chemoreception (résumé publié).
Z.W. Wolkowski,
J.-J. Godfroid,
Chemoreception Abstracts, 1975,
3,70
25*
A stereodynamic investigation of
antivitamines K in the dicoumarol series.
II. Differenciation between the two hydroxyl
groups by nuclear overhauser effect.
C.
Laruelle, J.-J.Godfroid,
Can. J. Chem., 1976, 54,
813.
26
Report on "European Summer School, First
Session", IUPAC, section of Medicinal
Chemistry (rapport).
J.-J. Godfroid,
R.F.
Rekker, Université Paris VII, Ed.,
1976.
27*
A quantitative structure-activity
approach to chemoreception: Importance of
lipophilic properties.
Z.W. Wolkowski, D. Moccatti,
F. Heymans,
J.-J. Godfroid
J. Theor. Biol., 1977, 66,
181-193.
28*
QSAR investigations in the uncoupling of
mitochondrial oxydative phosphorylation. II-
Use of spectroscopic parameters and
evaluation of the prediction of the
regressions in the dicoumarol series.
J.-J. Godfroid,
C. Deville, C. Laruelle,
Eur. J. Med. Chem., 1977,
12, 213-217.
29* Etude en RMN du carbone 13 de dicoumarols
substitués.
O. Convert, C. Deville, J.-J. Godfroid,
J. Org. Magn. Res., 1977,
10,220-223.
30*
Synthèse et propriétés des
aroylhydrazones du benzoate d'éthyle.
Synthèses d'hétérocycles azotés.
R.
Milcent, C. Redeuilh,
J. Het. Chem., 1977, 14,
55-58.
31*
Synthèse d'amino-4 aryl-3 (4H)
triazole-1,2,4 ones-5.
R.
Milcent, C. Redeuilh,
J. Het. Chem., 1979, 16,
403.
32*
Fragmentation sous l'impact électronique
d'amino-4 triazole-1,2,4 ones-5.
A.
Bernardini, P. Viallefond, R.
Milcent, Org.
Mass. Spect.,
1979, 14, 369.
33*
Quantitative Structure-Activity
Relationships for N-[(N',N'-disubstituted-amino)
acetyl]-arylamines for local anesthetic
activity and acute toxicity.
F. Heymans,
L. Le
Therizien,
J.-J. Godfroid,
P. Bessin,
J. Med. Chem., 1980, 23,
184-193.
34*
Partition coefficient additivity 1.
Morpholine and N- (N',N'-disubstituted amino
acetyl)-arylamines series.
L. Le
Therizien,
F. Heymans,
C. Redeuilh, J.-J. Godfroid,
N. Busch,
Eur. J. Med. Chem., 1980,
15, 311-316.
35*
Platelet Activating Factor (PAF-Acether):
total synthesis of 1-O-octadecyl 2-O-acetyl
sn-glycero-3-phosphoryl choline.
J.-J. Godfroid, F.
Heymans,
E. Michel,
C. Redeuilh, E. Steiner,
J. Benveniste,
FEBS Letters, 1980, 116,
161-164.
36*
Recherche en série triazole-1,2,4 :
réactivité des amino-4 aryl-3 triazol-1,2,4
ones-5.
C. Redeuilh,
R.
Milcent, J. Het. Chem.,
1980,17,1691.
37*
Nouvelle synthèse totale du "PAF-acéther"
et de son énantiomère.
F. Heymans,
E. Michel,
M.-C. Borrel, B. Wichrowski,
J.-J. Godfroid,
C.R. Acad. Sci., série II, 1981,
293, 49-52.
38*
Structural analogs of Platelet-Activating
Factor (PAF-Acether).
M. Tence,
E. Coeffier,
F. Heymans,
J. Polonsky,
J.-J. Godfroid,
J. Benveniste, Biochimie, 1981, 63, 723.
39*
New total synthesis and high resolution
1H NMR spectrum of Platelet-
Activating Factor (PAF-Acether), its
enantiomer and racemic mixture.
F. Heymans,
E. Michel,
M.C. Borrel,
B. Wichrowski, J.-J. Godfroid,
O.Convert,
E. Coeffier,
M. Tence,
J. Benveniste, Biochim. Biophys. Acta, 1981, 666,
230-237.
40*
Synthesis and biological activity of some
structural analogs of Platelet-Activating
Factor (PAF-Acether).
M. Tence, E. Michel, E. Coeffier,
J. Polonsky,
J.-J. Godfroid,
J. Benveniste, Agents and Action, 1981, 11,
558.
41*
Additional techniques for the total
synthesis of PAF-acether.
M.-C. Borrel,
C. Broquet,
F. Heymans,
E. Michel, C. Redeuilh,
B. Wichrowski,
J.-J. Godfroid,
Agents and Action, 1982, 12,
709-710.
42*
Biosynthesis of Platelet-Activating
Factor. I. Evidence for an
acetyl-transferase activity in murine
macrophages.
E. Ninio,
J.-M. Mencia-Huerta,
F. Heymans,
J. Benveniste,
Biochem. Biophys. Acta, 1982,
710, 23-31.
43*
Radio-labelling of 1-O-alkyl 2-O-acetyl
sn-glycero-3-phosphorylcholine, 1-O-(9,10-di
3H)-octadecyl PAF-acether.
J.-L. Morgat,
J. Roy,
B. Wichrowski,
E. Michel,
F. Heymans and J.-J. Godfroid,
Agents and Action, 1982, 12,
705-706.
44*
1H NMR of PAF-acether : Influence of
solvent on its structure.
O. Convert,
E. Michel,
F. Heymans,
J.-J. Godfroid,
Agents and Action, 1982,12,
706-708.
45*
Acide cyclohexyl-4
naphtalène-1-propionique.
L. Dupont, O. Dideberg, G. Dive,
J.-J. Godfroid, E. Steiner,
Acta Cryst., 1982,B 38, 2409.
46* Effect of structural analogues
of PAF-acether on platelet desensitization.
C. Lalau-Kéraly, E. Coeffier, M.
Tence, M.C. Borrel, J. Benveniste,
Brit. J. Haematol, 1983, 58,
307.
47*
A total synthesis of [9', 10'-3H]-labelled
PAF-acether.
B. Wichrowski,
E. Michel,
F. Heymans,
J. Roy,
J.L.Morgat,
J.-J. Godfroid,
J. Labelled Compounds and
Radiopharmaceuticals,
1983, 20, 991-998.
48*
Synthesis of PAF-acether and analogs
(publication dans cpte-rendu de colloque).
J.-J. Godfroid,
C. Broquet,
F. Heymans
in "Proceedings of the 1st International
Symposium on Platelet-Activating Factor", J.
Benveniste, B. Arnoux
Ed., Elsevier Science Publishers,
Amsterdam, 1983, 3-8.
49*
Effect of structural analogs of PAF-acether
on platelet aggregation and desensitization
(publication dans cpte-rendu de colloque) .
M. Tence,
E.
Coeffier,
C.
Lalau-Kéraly, C. Broquet
in "Proceedings of the 1st International
Symposium on Platelet-Activating Factor", J.
Benveniste,
B. Arnoux, Ed.,Elsevier Science Publishers, Amsterdam,
1983, 41-48.
50*
Structural analogs of PAF-acether. I.
Rac-acetyloxydocosyl phosphorylcholines.
C. Broquet, M.P. Teulade,
C. Borghero,
F. Heymans,
J.-J. Godfroid,
J. Lefort, E. Coeffier,
E. Pirotsky,
Eur. J. Med. Chem., 1984,
19, 229-233.
51*
1H-
and
13C-NMR
studies of platelet-activating factor
(PAF-acether) and analogs. Influence of
solvent.
O. Convert,
E. Michel,
F. Heymans,
J.-J. Godfroid,
Biochem.
Biophys. Acta,
1984, 794, 320-325.
52* Effet du chlorhydrate de (chloro-4
phénoxyacétate) de N-méthyl-hydroxyméthyl-3
pipéridine sur le comportement alimentaire.
Toxicité et neuropsychopharmacologie.
F. Massicot, J. Thuillier,
J.-J. Godfroid,
C.R., Acad. Sci., 1984, 299,
série III, 347-349.
53*
Structure-activity relationship in
PAF-acether. 2- Rac-1-O-octadecyl 2-O-acetyl
3-O-[g-dimethylaminopropyl]
glycerol.
F. Heymans,
M.-C. Borrel,
C. Broquet,
J. Lefort, J.-J. Godfroid,
J. Med. Chem., 1985, 28,
1094-1096.
54*
Synthesis and characterization of a
radioiodinated photoreactive and
physiologically active analogue of
Platelet Activating Factor.
P. Bette, A.
Bienvenue, C. Broquet, L. Maurin,
Chem. Phys. Lipids, 1985, 37,
215-226.
55* Activités métaboliques du chlorhydrate de
chloro-4 phénoxyacétate de N-méthyl
hydroxyméthyl-3 pipéridine chez les Rats
obèses.
F. Massicot, E. Steiner,
J.-J. Godfroid,
C.R., Acad. Sci., 1985, 300,
série III, 633-636.
56*
A tentative modelization of PAF-acether
(Platelet Activating Factor) binding site
deduced from a QSAR study.
J.-J. Godfroid, J.P. Robin, P.
Braquet, Prostaglandins,
1985, 30, 686.
57*
Activation of energy expenditure in the
rat by a new known non-amphetaminic
compound: the
(4-chlorophenoxyacetate)-N-methyl
3-hydroxymethyl piperidine, hydrochloride
(PM 170).
F. Massicot, D. Ricquier, J.-J. Godfroid,
M. Apfelbaum,
Int. J. Obesity, 1985, 9,
451-458.
58*
Antiobesity activity of a new cyclic amino
aryloxyacetate in obese mice and rats.
F. Massicot,
J.-P.
Batt, I. Tayarani, J. Thuillier,
J.-J. Godfroid,
Eur. J. Med.
Chem., 1985, 20, 559-562.
59* Mécanismes d'action du PM 170 dans
l'inhibition du développement de l'obésité
induite chez la Souris par
l'aurothioglucoseG
F. Massicot, R. Falcou, M.
Apfelbaum, J.-J. godfroid, Cahiers de Nutrition et de Diététique, 1986,
XXI, Fasc.1,53.
60*
Synthesis of Ether Phospholipids (revue).
J.-J. Godfroid, F. Heymans,
C. Broquet,
Pharm. Res. Comm., 1986, 18,
supplément, 1-10
61*
PAF-acether specific binding sites. I-
Quantitative SAR study of PAF-acether
isosters.
J.-J. Godfroid, P. Braquet,
Trends in Pharm. Sci., 1986,
7, 368-373.
62*
PAF-acether specific binding sites : II.
Design of specific antagonists.
J.-J. Godfroid, P. Braquet,
Trends in Pharm. Sci., 1986,
7, 397-403.
63*
Phosphorylation of class I HLA antigens in
U-937 monocyte-like cells: role of protein
kinase.
C.M. Rouis, P. Thomopoulos, A.
Haziot,
C. Broquet,
Experimental Cell Res., 1986,
164, 556-561.
64* Activités anti-obésité et
métaboliques du PM 170.
F. Massicot,
R. Falcou,
E. Steineir, F. Heymans,
J.-C. Lecomte, C. Redeuilh,
M. Apfelbaum,
J.-J. Godfroid,
Cahiers de Nutrition et de Diététique, 1986, XXI, Fasc. 6, 441.
65*
PM 170. A review.
F. Massicot,
J.-J. Godfroid,
Drugs of the Future,
1986, 11, n° 10, 848-850.
66* Effet lipolytique du
chlorhydrate de chloro-4 phénoxyacétate de
N-méthyl hydroxyméthyl-3 pipéridine.
F. Massicot, R. Falcou, E. Steiner,
J.-J. Godfroid,
C.R., Acad.Sci., 1986,
t. 300, Série III, n° 14, 617-619.
67* Activité antiobésité du
chlorhydrate de chloro-4 phénoxyacétate du
N-méthyl hydroxyméthyl-3 pipéridine chez des
souris traitées par l'aurothioglucose.
F. Massicot, G.Arapis, R. Falcou,
M. Apfelbaum, J.-J. Godfroid, C.R. Acad. Sci., 1986, t. 303,
Série III, n° 17, 703-708.
68*
Effects of PAF-acether and structural
analogs on platelet activation and
bronchoconstriction in guinea-pigs.
E. Coeffier,
M.C. Borrel,
J. Lefort,
M. Chignard, C. Broquet,
F. Heymans,
J.-J. Godfroid,
B.B. Vargaftig,
Eur. J. Pharmacol., 1986,
131, 179-188.
69* Conformational properties of
PAF-acether receptor in platelets based on
structure-activity studies (chapitre dans
ouvrage collectif).
P. Braquet,
J.-J. Godfroid
in "Platelet Activating Factor", F.
Snyder Ed., Plenum Press, New-York, 1987,
191-235.
70* Effects of a new anorectic
drug (PM 170) on development of gold
thioglucose-induced obesity in mice.
F. Massicot,
R. Falcou,
F. Heymans,
J.J. Godfroid, M. Apfelbaum,
Gen. Pharmacology, 1987, 18,
249-252.
71*
Endothelium-dependent vasorelaxation induced
by Cn-acetal plasmalogens.
P. Braquet, C. Broquet, M. Auguet,
J. Baranes, E. Etienne, J.-J. Godfroid,
Prostaglandins, Leukotrienes and Medicine,
1987, 26, 209-219.
72*
Alkyl analogs of diacylglycerol as
activators of protein kinase C.
F. Heymans,
C. Da
Silva, N. Marrec,
J.-J. Godfroid,
M. Castagna,
FEBS Letters, 1987,
218, 35-40.
73*
Structure-activity relationship in
PAF-acether. 3. Hydrophobic contribution to
the agonistic activity.
J.J. Godfroid, C. Broquet,
S. Jouquey,
M. Lebbar,
F. Heymans, C. Redeuilh,
E. Steiner,
E. Michel,
E. Coeffier, J. Fichelle,
M. Worcel,
J. Med.
Chem.,
1987, 30, 792-797.
74*
Etude par RMN
13C des interactions
intramoléculaires dans les benzènes para-disubstitués
: mise en évidence par régressions linéaires
de trois types de comportement.
F. Membrey, E. Steiner,
Spectrochimica Acta, 1987,
43 A, 593-604.
75*
Structure-activity relationship in
PAF-acether 4. Synthesis and biological
activities of carboxylate isosteres.
B. Wichrowski,
S. Jouquey,
C. Broquet,
F. Heymans,
J.-J. Godfroid,
J. Fichelle and M. Worcel,
J. Med. Chem., 1988, 31,
410-415.
76*
Chemistry of PAF antagonists (chapitre dans
ouvrage collectif).
J.-J. Godfroid, F. Heymans,
in Progress in Biochemical Pharmacology,
Platelet Activating Factor, S. Karger A.G,
Eds, Bâle, 1988, 22, 25-34.
77*
PAF receptor. 1- "Cache-Oreilles" effect of
selected high potency Platelet-Activating
Factor PAF) antagonists.
G. Dive,
J.-J. Godfroid,
J. Lamotte-Brasseur,
J.-P. Batt,
F. Heymans,
L .
Dupont,
P. Braquet, J. Lip. Med., 1989, 1, 201-215.
78*
PAF receptor. 2- Quantitative hydrophobic
contribution of the agonist's etheroxid
chain.
F. Heymans,
E. Steiner,
S. Jouquey,
J.-J. Godfroid,
J. Lip. Med., 1989, 1,
303-312.
79*
PAF-receptor agonists. Structure-activity
relationships (chapitre dans ouvrage
collectif).
J.-J. Godfroid, G. Dive,
Platelet Activating Factor in Endotoxin
and Immune Diseases, Houlihan Ed.,
Marcel Dekker Press, New York, 1990,15-30.
80*
PAF-receptor. 1- Conformational and
electronic properties of PAF-like agonists
and antagonists.
J. Lamotte-Brasseur,
G. Dive, F. Heymans,
J.-J. Godfroid,
J. Lip. Med., 1990, 2,
208.
81*
PAF-receptor -3- "Cache-Oreilles" effect in
simplified PAF-antagonists (résumé publié).
J.-P. Batt,
F. Heymans,
A. Lamouri,
C. Redeuilh, G. Dive,
J. Lamotte-Brasseur,
D. Hosford, P. Braquet,
J.-J. Godfroid,
J. Lip. Med., 1990, 2,
209.
82*
PAF-receptor. 4 - Piperazine derivatives as
antagonists of PAF.
(Résumé publié).
A. Lamouri,
F. Tavet,
F. Heymans, J.P. Batt,
G. Dive,
J. Lamotte-Brasseur,
N. Blavet,
E. Pirotsky,
J.-J. Godfroid,
J. Lip. Med., 1990, 2,
209.
83*
Structure-activity relationships in
platelet activating factor (PAF) 5.
Synthesis and in vitro antagonistic
activities of ketophosphonates.
A. Furno - de Winter, C.
Broquet, J.-P. Haelters, F. Massicot, G.
Sturtz,
J.-J. Godfroid,
J. Lip. Med., 1991, 3,
289-300.
84*
Platelet Activating Factor Antagonists
Structure of N, N' Bis
-(3,4,5-trimethoxy-benzoyl)-2-piperazinylméthyl
2,2-dimethylpropanoate.
B. Stensland, J.-P. Batt, A.
Lamouri,
J.-J. Godfroid,
Acta Crys., 1991, C 47,
1453-1457.
85*
PAF-receptor III- Conformational and
electronic properties of PAF-like agonists
and antagonists.
J. Lamotte-Brasseur,
G. Dive, A. Lamouri,
F. Heymans,
J.-J. Godfroid,
Biochem.
Biophys. Acta
, 1991, 1085, 91-105.
86*
Structure of PAF-receptor : a hypothesis.
J.-J. Godfroid, G. Dive,
J. Lamotte-Brasseur,
J.-P. Batt, F. Heymans,
Lipids, PAF special issue, 1991,
26, 1162-1166.
87*
PAF-receptor and "Cache-oreilles" Effect.
Simple chain PAF-antagonists.
J. Lamotte-Brasseur,
F. Heymans, G. Dive,
A. Lamouri,
J.-P. Batt,
D. Hosford,
C. Redeuilh,
P. Braquet,
J.-J. Godfroid,
Lipids, PAF special issue, 1991,
26, 1167-1171.
88*
New hypothesis on the conformation of the
PAF-receptor from studies on the geometry of
selected platelet-activating factor
antagonists.
J.-P. Batt,
A. Lamouri,
F.Tavet,
F. Heymans, G. Dive,
J.-J. Godfroid,
J. Lip. Med., 1991, 4,
343-346.
89*
Structure-activity relationship in
platelet-activating factor (PAF). 6-
Synthesis and in vitro antagonistic
activities of 5-substituted
2-oxotetrahydrofurans.
E. Favre,
F. Heymans,
C. Redeuilh, J.-P. Batt,
F. Massicot,
P. Braquet,
J.-J.Godfroid, J. Lip. Med.,1992, 5,
23-40.
90*
Production and characterization of specific
antibodies to Platelet-Activating factor.
J. L. Macpherson,
B. Spur,
S. G. Pyne,
F. Heymans,
M. F. Cox,
J.-J. Godfroid,
S.A. Krilis, J. Lip. Med., 1992, 5, 49-59.
91*
Design and Modeling of New
Platelet-Activating Factor Antagonists. 1-
Synthesis and Biological Activity of 1,4-bis
(3',4',5'-trimethoxybenzoyl)-2-[[(substituted
carbonyl and carbamoyl) oxy] methyl]
piperazines.
A. Lamouri, F. Heymans, F. Tavet,
G. Dive, J.-P. Batt, N. Blavet, P. Braquet,
J.-J. Godfroid, J. Med. Chem.,
1993, 36, 990-1000.
92*
Design and Modeling of New
PAF-Antagonists:
1,4-Bis-(3',4',5'-Trimethoxybenzoyl)-2-substituted
carbonyloxymethyl piperazines.
F. Heymans, A. Lamouri, J.-P.
Batt, G. Dive, J.-J. godfroid,
J. Lip. Med. Cell Sign., 1994,
10, 153-154.
93*
Structure of
5-(3,4,5-trimethoxyphenyl)-2-iodomethyl
tetrahydrofuran: A Precursor of
Acetylcholinesterase Inhibitors with
Platelet-Activating Factor Antagonistic
Activity.
L. Le Texier, E. Favre, J.-J. Godfroid,
Acta Cryst.,
1995,
B 51, 863-867.
94*
Electrolyte permeability and potential
study of human basement membrane.
S. Achour, B. Tao Fan, C. Gavach,
D. Guerin, J.-J. Godfroid,
J.
Chim. Phys. 1995,
92, 1629-1645.
95*
Structure-Activity Relationships (SAR) in
Platelet-Activating Factor (PAF). 7- Dual
PAF and Acetylcholinesterase Inhibitors
derived from Tetrahydrofuran: synthesis and
PAF-antagonistic activity
L. Le Texier, E. Favre, C.
Redeuilh, F. Massicot, N. Blavet, E.
Pirotzky, J.-J. Godfroid,
J. Lip. Med.Cell Sign.,
1996, 13, 189-205.
96*
Structure-Activity Relationships (SAR) in
Platelet-Activating Factor (PAF). 8. Dual
PAF and Acetylcholinesterase Inhibitors
derived from Tetrahydrofuran: comparative
SAR of both activities
L. Le Texier, E. Favre, C.
Redeuilh, F. Massicot, N. Blavet, E.
Pirotzky, J.-J. Godfroid,
J. Lip. Med.Cell Sign.,
1996, 13, 207-222.
97*
Effects of S21663 (PMS 812), an imidazoline
derivative, on glucose tolerance and insulin
secretion in rat model of type II diabetes.
X. Wang, F. Rondu, A. Lamouri, R. Dokhan, S.
Marc, E. Touboul, B. Pfeiffer, D. Manechez,
P. Renard, B. Guardiola-Lemaitre, J.-J.
Godfroid, A. Ktorza,
L. Penicaud,
J. Pharmacol. Exp. Ther.,
1996, 278, 82-89
98*
4-Alkoxybenzamidines as potent phospholipase
A2 inhibitors
M. Aitdafoun, C. Mounier, F. Heymans, C.
Binisti, C. Bon, J.-J. Godfroid,
Biochem. Pharmacol., 1996,
51, 737-742
99*
Structure-Activity Relationships in
Platelet-Activating Factor (PAF). 9- From
PAF-antagonism to Phospholipase A2
inhibition.
C. Binisti, E. Touboul, C.
Mounier, F. Heymans, C. Bon, J.-J.Godfroid,
J.
Lip. Med.Cell Sign.,
1997,
15, 125-144.
100* Design and Modeling of New
Platelet-Activating Factor Antagonists. 2-
Synthesis and biological activity of
1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl
and etheroxy-piperazines.
F.
Tavet,
A.
Lamouri, F.
Heymans, G. Dive,
E.
Touboul,
N. Blavet, J.-J.
Godfroid, J. Lip. Med.Cell
Sign., 1997, 15, 145-159.
101*
Design and Modeling of New
Platelet-Activating Factor Antagonists. 3-
Relative importance of hydrophobicity and
electronic distribution.
F.
Heymans, G. Dive,
A.
Lamouri,
T.
Bellahsene, E.
Touboul, F.
Tavet,
C. Redeuilh, J.-J.
Godfroid,
J. Lip. Med. Cell Sign.,
1997, 15, 161-173.
102*
Preventive effects of two PAF-Antagonists,
PMS 536 and PMS 549 on cyclosporin-induced
oxidative injury.
F. Massicot, A. Lamouri, C.
Pham-Huy, C. Martin, F. Heymans, J.M.
Warnet, J.-J. Godfroid,
J.R. Claude, J. Lip. Med.
Cell Sign.., 1997, 15,
203-215 (2).
103*
A new phospholipase A2 inhibitor, unrelated
to substrate analogues: kinetic
characterization of the inhibition of
secretory phospholipases A2 by PMS 832.
C. Binisti, C. Mounier, E.
Touboul, F. Heymans, C. Bon, J.-J.
Godfroid,
J. Lip. Med. Cell. Sign., 1997,
16, 171-187.
104*
Design and Synthesis of Imidazoline
Derivatives Active on Glucose Homeostasis in
a Rat Model of Type II Diabetes.1- Synthesis
and Biological activities of
N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines.
F. Rondu, G. Le Bihan, X. Wang,
E. Touboul, A. Lamouri, E. Touboul, G. Dive,
T. Bellahsene, B. Pfeiffer, P. Renard, B.
Guardolia-Lemaître, D. Manechez, L.
Pénicaud, A. Ktorza, J.-J. Godfroid,
J. Med. Chem.,
1997, 40, 3793-3803.
105*
Stimulation
of insulin release from the MIN6 cell line
by a new imidazoline compound S-21663 (PMS
812): evidence for the existence of a novel
imidazoline site in
b
cells.
L. Le Brigand, A. Virsolvy, K.
Peyrollier, D. Manechez, J.-J. Godfroid,
B. Guardolia-Lemaître, D. Bataille,
British J. Pharmacology, 1997,
122, 786-791.
106*
Effective stereoselective total synthesis of
16, 16-dimethyl prostaglandin E2.
A. Rodríguez, M. Nomen, B. W. Spur ,
J.-J. Godfroid,
Arch. Pharm. Pharm. Med. Chem.
1998, 331, 279-282
107*
A Selective method for the preparation of
aliphatic methyl esters in the presence of
aromatic carboxylic acids.
A. Rodríguez, M. Nomen, B. W. Spur
, J.-J. Godfroid,
Tetrahedron Lett. 1998, 39,
8563-8566.
108 *
Effect of the new imidazoline derivative
S-22068 (PMS 847) on insulin secretion in
vitro and glucose turnover in vivo in rats.
A. Pelé-Tounian, S. L. F. Chan, F. Rondu,
G. Le Bihan, M. H. Giroix, A. Lamouri, E.
Touboul, B. Pfeiffer, D. Manechez, P.
Renard, B. Guardolia-Lemaître, J.-J.
Godfroid, L. Pénicaud, F. Rondu, N. G.
Morgan, A. Ktorza,
Eur.
J. Pharmacol.,
1999, 377, 81-87.
109* Synthesis of 2H3-labelled
misoprostol and its primary plasma
metabolite.
A.
Rodríguez, M. Nomen, B. W. Spur , J.-J.
Godfroid, J. Labelled Cpd.
Radiopharm. 1999, 42,
843-850.
110*
Design and Synthesis of Imidazoline
Derivatives Active on Glucose Homeostasis in
a Rat Model of Type II Diabetes. 2-
Synthesis and Biological activities of
N-N'-dialkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl).
G. Le
Bihan, F. Rondu, A. Pelé-Tounian, X. Wang,
S. Lidy E. Touboul, A. Lamouri A, G. Dive,
J. Huet, B. Pfeiffer, P. Renard , B.
Guardiola-Lemaître D. Manéchez, L.Pénicaud,
A. Ktorza, J.-J. Godfroid,
J. Med. Chem., 1999, 42,
1587-603.
111*
Selective oxidation of primary silyl ethers
and its application to the synthesis of
natural products.
A. Rodríguez, M. Nomen, B. W. Spur
, J.-J. Godfroid,
Tetrahedron Lett. 1999, 40,
5161-5164.
112*
An efficient asymmetric synthesis of
prostaglandin E1.
A. Rodríguez, M. Nomen, B. W. Spur
, J.-J. Godfroid,
Eur. J. Org. Chem., 1999,
2655-2662.
113*
PMS-601, a new platelet-activating factor
receptor antagonist that inhibits human
immunodeficiency virus replication and
potentiates zidovudine activity in
macrophages.
M. Martin, N. Serradji, N.
Dereuddre-Bosquet, G. Le Pavec, G. Fichet,
A. Lamouri, F. Heymans, J.-J. Godfroid,
P. Clayette, D. Dormont, Antimicrob.
Agents Chemother., 2000,
44, 3150-4.
114*
Structure-activity relationships in
platelet-activating factor (PAF). 10. From
PAF antagonism to inhibition of HIV-1
replication.
N. Serradji, O. Bensaid, M. Martin,
O. Kan, N. Dereuddre-Bosquet, C. Redeuilh,
J. Huet, F. Heymans, A. Lamouri, P.
Clayette, C. Z. Dong, D. Dormont , J.-J.
Godfroid,
J. Med. Chem., 2000, 43,
11, 2149-54.
115*
Total synthesis of lipoxin A4 and
lipoxin B4 from butadiene.
A. Rodríguez, M. Nomen, B. W. Spur
, J.-J. Godfroid,
T.H. Lee, Tetrahedron Lett. 2000, 41,
823-826.
116*
Antiretroviral ant anti-inflammatory
properties of a novel platelet activation
factor antagonist, PMS-601.
M. Martin, N. Serradji, N.
Dereuddre-Bosquet, O. Bensaïd, G. Fichet ,
A. Lamouri, F.
Heymans, P. Clayette, J.-J. Godfroid, D. Dormont,
Pathol Biol (Paris), 2000,
48 , 513-9.
117*
ATPase activity in CFTR-enriched apical
membrane vesicles from tracheal epithelium.
H. Villette, L.G. Lelièvre,
Biochim. Biophys. Acta (Biomembranes),
2000, 1467, 7-17.
118*
Total synthesis of leukotrienes from
butadiene.
A. Rodríguez, M. Nomen, B. W. Spur ,
J.-J. Godfroid,
T.H.
Lee, Eur. J. Org. Chem.
2000, 2991-3000.
119*
Propriétés antirétrovirales et
anti-inflammatoires d’un nouvel antagoniste
du facteur d’activation des plaquettes, le
PMS-601.
M. Martin, N. Serradji, N. Derreudre-Bosquet,
O. Bensaid, A. Lamouri, F. Heymans, P.
Clayette, J.-J. Godfroid, D. Dormont,
Pathol.
Biol.
2000, 83, 513-519.
120*
Structure-Activity relationships on
adrenoceptors and imidazoline-preferring
binding sites (I1,2-PBSs). Part 1 : weak
intramolecular H-bond and conformational
flexibility in a new I1-PBS-selective
imidazoline analogue, trans
1-(4’,5’-dihydro-1’H-imidazol-2’-yl)methyl-2-hydroxyindane
(PMS 952).
H.F. Ye, G. Dive, D. Dehareng,
F. Heymans , J.-J. Godfroid,
Bioorg. Med. Chem., 2000,
8, 1861-1869.
121*
Total synthesis of 12(R)-HETE, 12(S)-HETE,
2H2 -12(R)-HETE and
LTB4 from racemic glycidol via
hydrolytic kinetic resolution.
A. Rodríguez, M. Nomen, B. W. Spur
, J.-J. Godfroid,
T.H. Lee, Tetrahedron, 2001, 57,
25-37.
122*
Expression of functionnal Na+/K+
- ATPase isozymes in normal human cardiac
biopsies.
L.G. Lelievre, G. Cramberg & P.D.
Allen,
Cell. Mol. Biol.
2001, 47, 265-271.
123*
Structure-Activity Relationships in
Platelet-Activating Factor (PAF). 11- From
PAF-Antagonism to Phospholipase A2
Inhibition: Syntheses and Structure-Activity
Relationships in
1-Arylsulfamido-2-Alkylpiperazines.
C. Binisti, L. Assogba, E.
Touboul, C. Mounier, F. Heymans, J. Huet,
J.-E. Ombetta, C.–Z. DonG, J.-J. Godfroid,
Eur. J. Med. Chem., 2001,
36, 809-828.
124*
Transport and Pharmacological Properties of
nine Different Human Na, K-ATPase Isozymes.
G. Cramberg , U. Hasler, A.T.
Beggah, C. Yu, N.N. Modyanov, J.-CD.
Horisberger, L.G. Lelievre, & K. Geering,
J. Biol. Chem. 2001, 47,
265-271.
125*
Total direct chemical synthesis and
biological activities of human group IIA
secretory phospholipase A2.
C.-Z. Dong, A. Romieu, C.M. Mounier,
F. Heymans, B.P. Roques, J.-J. Godfroid,
Biochem. J., 2002, 365,
505-511.
126*
Hydroindenic amidinohydrazones – Synthesis
and evaluation as inotropic agents.
L.G. Sevillano, C.P. Melero, E.
Caballero, F. Tome, M. Medarne, L.G.
Lelièvre & K. Geering, J. Med. Chem.
2002, 45, 127-136.
127*
Structure-Activity Relationships in
Platelet-Activating Factor (PAF). 12.
Synthesis and Biological Evaluation of
Piperazinic Derivatives as Antiretroviral
and Anti-PAF Compounds.
N. Serradji, M. Martin, O.
Bensaid, S. Cisternino, C. Rousselle, J.
Huet, C. Redeuilh, A. Lamouri,
C.-Z. Dong, P. Clayette, J.-J. Godfroid,
J.-M. Scherrmann, D. Dormon, F. Heymans,
J. Med. Chem. 2004,
47, 6410-6419.
128*
Inhibition of secretory phospholipase A2.
2- Synthesis and structure-activity
relationship studies of
4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one
(PMS1062) derivatives specific for group II
enzyme.
C.Z. Dong, A. Ahamada-Himidi, S.
Plocki, N. Meddad-Belhabich, D. Aoun, M.
Touaibia, J. Huet, C. Redeuilh, J.-E.
Ombetta, J.-J. Godfroid, F., F.
Heymans,
Bioorg.
Med. Chem.,
2005, 13, 1989-2007
129*
Inhibition of secretory phospholipase A2.
1-design, synthesis and structure-activity
relationship studies starting from
4-tetradecyloxybenzamidine to obtain
specific inhibitors of group II sPLA2s.
L.
Assogba, A. Ahamada-Himidi, N. M. Habich, L.
Aoun D,Boukli, F. Massicot, C. M. Mounier,
J. Huet, A. Lamouri, J.-E. Ombetta, J.-J.
Godfroid , C. Z. Dong, F. Heymans,
Eur. J. Med. Chem., 2005,
40, 850-61.
130*
Inhibition of secretory PLA2. 3- Molecular
modeling and synthesis of less lipophilic
derivatives of
4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one
(PMS1062), specific for group II enzyme.
S. Plocki, D. Aoun, A. Ahamada-Himidi, F.
Tavares-Camarinha, C.Z. Dong, F. Massicot,
J. Huet, S. Adolphe-Pierre, F. Chau,
J.-J. Godfroid, N. Gresh, J.E. Ombetta &
F. Heymans,
Eur. J. Org. Chem., 2005,
2747–2757.
Consulter :
Google : « JJ Godfroid » et « Jean-Jacques
Godfroid »
Labmeeting :
http://www.labmeeting.com/papers/author/godfroid-jj
Biomed Experts (JJ G = « top expert » pour
le « Platelet Activating Factor » ….):
http://www.biomedexperts.com/Profile.bme/471460/Jean-Jacques_Godfroid
|
